STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2007 by analyst upside · 2026-06-27
TNGX
Tango Therapeutics, Inc.
Healthcare · Market Cap $5B · P/E 0x
ANALYST PRICE TARGET
+28.5%
implied upside to consensus target
Current Price $31.47
Consensus Target $40.45
Bull Target $69.0
Bear Target $24.0
Analysts Covering 11
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
9
Hold
1
Sell
0
52-Week Low $4.8
52-Week High $34.39
YTD Return +252.4%
FUNDAMENTALS
Market Cap $5B
P/E Ratio (TTM) N/A
Forward P/E -19.9x
EPS (TTM) $-0.83
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $57M
Profit Margin -188.2%
52-WEEK RANGE
52-Week Low $4.8
52-Week High $34.39
Current Price $31.47
Bear Target $24.0
Bull Target $69.0
● Now $31.47 ● Target $40.45
TRADING DATA
Avg Volume 3.9M
YTD Return +252.4%
Analyst Count 11
Consensus Buy
Upside to Target +28.5%
Last Updated 2026-06-27

ANALYST SUMMARY

Tango Therapeutics, Inc. (TNGX) is currently trading at $31.47 with a Wall Street consensus price target of $40.45, implying potential upside of 28.5% over the next 12 months. 11 analysts currently cover TNGX, with a consensus rating of Buy - 91% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $69.0, while the most cautious has a target of $24.0.

TNGX operates in the Healthcare sector with a market capitalisation of $5B. The stock is up 252.4% year-to-date and is currently trading near the upper end of its 52-week range of $4.8 – $34.39.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for TNGX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Canaccord Genuity — Reiterated
Buy → Buy 2026-06-11 Building track record
HC Wainwright & Co. — Reiterated
Buy → Buy 2026-06-09 31% win rate (48 calls)
Canaccord Genuity — Reiterated
Buy → Buy 2026-06-09 Building track record
Leerink Partners — Reiterated
Outperform → Outperform 2026-06-08 29% win rate (7 calls)
Mizuho — Reiterated
Outperform → Outperform 2026-05-15 Building track record
Piper Sandler ↓ Downgrade
Overweight → Neutral 2026-05-15 14% win rate (7 calls)
Jefferies ↓ Downgrade
Buy → Hold 2026-05-14 50% win rate (6 calls)
Leerink Partners — Reiterated
Outperform → Outperform 2026-05-14 29% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
42
out of 100
Coverage depth
19/30
Consensus clarity
1/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →